|
1.
|
|
7 p, 5.6 MB |
Results of ARI-0001 CART19 Cells in Patients With Chronic Lymphocytic Leukemia and Richter's Transformation
/
Ortiz-Maldonado, Valentín (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Frigola, Gerard (Hospital Clínic i Provincial de Barcelona) ;
Español-Rego, Marta (Hospital Clínic i Provincial de Barcelona) ;
Balagué, Olga (Hospital Clínic i Provincial de Barcelona) ;
Martínez Cibrián, Núria (Hospital Clínic i Provincial de Barcelona) ;
Magnano, Laura (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Giné, Eva (Centro de Investigación Biomédica en Red de Cáncer) ;
Pascal, Mariona (Hospital Clínic i Provincial de Barcelona) ;
Correa, Juan G. (Hospital Clínic i Provincial de Barcelona) ;
Martínez-Roca, Alexandra (Hospital Clínic i Provincial de Barcelona) ;
Cid, Joan (Hospital Clínic i Provincial de Barcelona) ;
Lozano, Miquel (Universitat de Barcelona. Departament de Medicina) ;
Villamor, Neus (Hospital Clínic i Provincial de Barcelona) ;
Benítez Ribas, Daniel (Hospital Clínic i Provincial de Barcelona) ;
Esteve Reyner, Jordi (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
López Guillermo, Armando (Universitat de Barcelona. Departament de Medicina) ;
Campo, Elias (Hospital Clínic i Provincial de Barcelona) ;
Urbano Ispizua, Álvaro (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Juan, Manel (Universitat de Barcelona. Departament de Medicina) ;
Delgado, Julio (Universitat de Barcelona. Departament de Medicina)
CART19 cells are emerging as an alternative therapy for patients with chronic lymphocytic leukemia (CLL). Here we report the outcome of nine consecutive patients with CLL treated with ARI-0001 CART19 cells, six of them with Richter's transformation (RT). [...]
2022 -  10.3389/fonc.2022.828471
Frontiers in Oncology, Vol. 12 (31 2022) , p. 828471
|
|
|
2.
|
|
27 p, 3.4 MB |
T cells isolated from G-CSF-treated multiple myeloma patients are suitable for the generation of BCMA-directed CAR-T cells
/
Battram, Anthony M (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Oliver-Caldés, Aina (Hospital Clínic i Provincial de Barcelona) ;
Suárez Lledó, Maria (Hospital Clínic i Provincial de Barcelona) ;
Lozano, Miquel (Hospital Clínic i Provincial de Barcelona) ;
Bosch i Crespo, Miquel (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Martínez Cibrián, Núria (Hospital Clínic i Provincial de Barcelona) ;
Cid, Joan (Hospital Clínic i Provincial de Barcelona) ;
Moreno, David F. (Hospital Clínic i Provincial de Barcelona) ;
Rodríguez Lobato, Luis Gerardo (Hospital Clínic i Provincial de Barcelona) ;
Urbano Ispizua, Álvaro (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Fernández de Larrea, Carlos (Universitat de Barcelona)
Autologous cell immunotherapy using B cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR)-T cells is an effective novel treatment for multiple myeloma (MM). This therapy has only been used for relapsed and refractory patients, at which stage the endogenous T cells used to produce the CAR-T cells are affected by the immunosuppressive nature of advanced MM and/or side effects of previous therapies. [...]
2022 - 10.1016/j.omtm.2022.06.010
Molecular Therapy. Methods & Clinical Development, Vol. 26 (august 2022) , p. 207-223
|
|
|
3.
|
|
5 p, 765.8 KB |
Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma
/
Iacoboni, Gloria (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Rejeski, Kai (Department of Medicine III, University Hospital, LMU Munich, Munich, Germany) ;
Villacampa Javierre, Guillermo (Vall d'Hebron Institut d'Oncologia) ;
van Doesum, Jaap A. (Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands) ;
Chiappella, Annalisa (Division of Hematology and Stem Cell Transplantation, Fondazione IRCCS Istituto Nazionale dei Tumori, University of Milano, Milano, Italy) ;
Bonifazi, Francesca (IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia "Seràgnoli", Bologna, Italy) ;
López Corral, Lucia (Centro de Investigación del Cáncer-IBMCC, Salamanca, Spain) ;
van Aalderen, Michiel (Department of Hematology, Amsterdam University Medical Centers, Cancer Center Amsterdam, LYMMCARE (Lymphoma and Myeloma Center Amsterdam), Amsterdam, The Netherlands) ;
Kwon, Mi (Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM)) ;
Martínez-Cibrian, Nuria (Hospital Clínic i Provincial de Barcelona) ;
Bramanti, Stefania (Istituto Clinico Humanitas IRCCS, Rozzano, Italy) ;
Reguera-Ortega, Juan Luis (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Camacho-Arteaga, Lina (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ;
Schmidt, Christian (Department of Medicine III, University Hospital, LMU Munich, Munich, Germany) ;
Marín-Niebla, Ana (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Kersten, Marie José (Department of Hematology, Amsterdam University Medical Centers, Cancer Center Amsterdam, LYMMCARE (Lymphoma and Myeloma Center Amsterdam), Amsterdam, The Netherlands) ;
Martín García-Sancho, Alejandro (Instituto de Investigación Biomédica de Salamanca) ;
Zinzani, Pier Luigi (Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Università di Bologna, Bologna, Italy) ;
Corradini, Paolo (Division of Hematology and Stem Cell Transplantation, Fondazione IRCCS Istituto Nazionale dei Tumori, University of Milano, Milano, Italy) ;
van Meerten, Tom (Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands) ;
Subklewe, Marion (Department of Medicine III, University Hospital, LMU Munich, Munich, Germany) ;
Barba, Pere (Universitat Autònoma de Barcelona. Departament de Medicina)
2022 - 10.1182/bloodadvances.2021006922
Blood advances, Vol. 6 (june 2022) , p. 3606-3610
|
|
|
4.
|
|
10 p, 674.7 KB |
Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma
/
Iacoboni, Gloria (Vall d'Hebron Institut d'Oncologia) ;
Villacampa Javierre, Guillermo (Vall d'Hebron Institut d'Oncologia) ;
Martinez-Cibrian, Nuria (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Bailén, Rebeca (Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM)) ;
Lopez Corral, Lucia (Centro de Investigación del Cáncer-IBMCC) ;
Sanchez, Jose M. (Hospital Universitario 12 de Octubre (Madrid)) ;
Guerreiro, Manuel (Hospital Universitari i Politècnic La Fe (València)) ;
Caballero, Ana Carolina (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Mussetti, Alberto (Institut Català d'Oncologia) ;
Sancho, Juan-Manuel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Hernani, Rafael (Hospital Clínic Universitari (València)) ;
Abrisqueta, Pau (Vall d'Hebron Institut d'Oncologia) ;
Solano, Carlos (University of Valencia) ;
Sureda, Anna (Institut Català d'Oncologia) ;
Briones Meijide, Javier (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Martín García-Sancho, Alejandro (Centro de Investigación del Cáncer-IBMCC) ;
Kwon, Mi (Hospital General Universitario Gregorio Marañón. Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM)) ;
Reguera-Ortega, Juan Luis (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Barba, Pere (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona
Tisagenlecleucel (tisa-cel) is a second-generation autologous CD19-targeted chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). The approval was based on the results of phase II JULIET trial, with a best overall response rate (ORR) and complete response (CR) rate in infused patients of 52% and 40%, respectively. [...]
2021 - 10.1002/cam4.3881
Cancer Medicine, Vol. 10 (may 2021) , p. 3214-3223
|
|
|
5.
|
|
6 p, 378.5 KB |
Quantitative PCR Is Faster, More Objective, and More Reliable Than Immunohistochemistry for the Diagnosis of Cytomegalovirus Gastrointestinal Disease in Allogeneic Stem Cell Transplantation
/
Suárez-Lledó, M. (Hospital Clínic i Provincial de Barcelona) ;
Marcos, Maria Angeles (Institut de Salut Global de Barcelona) ;
Cuatrecasas, Miriam (Hospital Clínic i Provincial de Barcelona) ;
Bombi, J. A. (Hospital Clínic i Provincial de Barcelona) ;
Fernandez Aviles, Francesc (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Magnano, Laura (Hospital Clínic i Provincial de Barcelona) ;
Martínez-Cibrián, N. (Hospital Clínic i Provincial de Barcelona) ;
Llobet, N. (Hospital Clínic i Provincial de Barcelona) ;
Rosiñol Dachs, Laura (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Gutiérrez-García, Gonzalo (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Jorge, S. (Hospital Clínic i Provincial de Barcelona) ;
Martínez Muñoz, Carmen (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Rovira Tarrats, Montserrat (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Urbano Ispizua, Álvaro (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Universitat Autònoma de Barcelona
Diagnosis of gastrointestinal (GI) cytomegalovirus (CMV) disease relies on the presence of GI symptoms and detection of CMV, mainly by immunohistochemistry (IHC), in GI biopsy specimens. Thus, in a symptomatic patient, a positive CMV-IHC result is accepted as a diagnosis of CMV disease. [...]
2019 - 10.1016/j.bbmt.2019.07.016
Biology of blood and marrow transplantation, Vol. 25 Núm. 11 (november 2019) , p. 2281-2286
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
